Ashwagandha: Dosage, Evidence, Safety, Price

01

Names, aliases and forms

Common Namesashwagandha; Indian ginseng; winter cherry

Latin NameWithania somnifera

Traditional Nameashvagandha

02

Potential effects and evidence map

Systematic reviews report promising but limited short-term signals for stress-tension and night-rest outcomes, with small trial counts, varied extracts, and heterogeneity. A 2026 review reported cognition and training-strength signals across adult trials, but product identity, dose, population, and outcome differences make broad focus, memory, and performance claims too strong for a comparison page. Safety evidence is less complete than benefit evidence, so product choice should weigh liver, thyroid, hormone, immune, sedating, and drug-overlap context.

Effect domainMagnitudeGrade

Stress resilience⁴

CumulativeConfidence: Medium

Short-term adult trials show stress-tension score signals, but extract type, dose, and population differences limit certainty.

Note Use stress-resilience language, not disease-treatment or guaranteed calm claims.

3/5

B

Calm / relaxation⁴

CumulativeConfidence: Medium

Some users may notice calmer stress response over weeks, but the evidence is not a one-dose sedative guarantee.

Note Keep distinct from acute tranquilizer-style positioning.

2/5

B

Memory / learning⁶

CumulativeConfidence: Low

Recent meta-analysis reports cognitive-domain signals, but broad memory and focus claims remain product-form-dependent and not settled.

Note Avoid legacy-style broad cognition and mental-performance claims.

1/5

C

Physical energy / endurance⁶

CumulativeConfidence: Low

Training-strength signals appear in some adult trials, but they do not establish a general energy or performance product for every user.

Note Avoid broad performance marketing and compare extract identity first.

1/5

C

03

Typical dosages and timing

Typical

300-600 mg/day

Not a recommendation

Lower bound

300 mg/day

Profile value

Upper bound

600 mg/day

Profile value

common oral range⁵300-600 mg/day

Many trials and products cluster around 300-600 mg/day of extract, but labels vary by extract ratio, withanolide standardization, and whether root or root/leaf material is used. Do not compare capsules by milligrams alone.

04

Onset, duration and tolerance

Onset1-2 hours

Duration2-6 hours

Half-life2-4 hours

Study duration⁷8-12 weeks

Peak levels⁸1-2 hours

Acute window⁹2-6 hours

Study windows are usually weeks, not acute guarantees⁷

Most stress, anxiety, and sleep trials evaluate daily use over several weeks. This is the evidence window for sustained benefits, not a single-dose effect duration or recommended cycle.

Plasma timing is extract-dependent⁸

Human pharmacokinetic work found extract-dependent withanolide plasma peaks in roughly this range after a single dose. Plasma timing supports an acute window, but it does not prove the same timing for every subjective effect.

Same-day effects are plausible, but not social-anxiety-specific proof⁹

A same-day calming or social-ease effect is plausible for some users, and acute trials have measured cognition, attention, fatigue, tension, or related markers over several hours. Social-anxiety-specific acute trials are still lacking, so this window is best treated as practical context rather than a proven indication.

05

Safety, side effects and risk profile

Main safety filters before comparing prices¹

Treat ashwagandha as a low-risk supplement for typical short-term oral use in generally healthy adults, with targeted caution when pregnancy, lactation, liver disease history, thyroid treatment, hormone-sensitive conditions, autoimmune conditions, upcoming surgery, sedating stacks, diabetes drugs, blood-pressure drugs, immune-suppressing drugs, anticonvulsants, or thyroid-hormone drugs are relevant.

Liver / kidney caution³

Confidence: High

Case series and hepatotoxicity reviews link ashwagandha products to cholestatic or mixed liver injury in rare users.

Note BfR advises people with acute or prior liver disease to avoid these supplements.

4/5

C

Pregnancy / lactation caution¹

Confidence: High

Government and regulatory sources advise avoiding use during pregnancy and lactation because safety data are inadequate and risk concerns exist.

Note Keep this as an avoid-group warning, not a dose-adjustment note.

4/5

B

Hormonal caution²

Confidence: Medium

Ashwagandha may matter for thyroid, cortisol, glucose, testosterone, autoimmune, and hormone-sensitive contexts.

Note NCCIH and BfR both flag endocrine or immune-system caution; thyroid case reports exist.

3/5

C

Sedation / impairment¹

Confidence: Medium

Drowsiness can occur, and sedating stacks may impair driving, machinery, or next-day alertness.

Note Separate calming/rest positioning from impairment risk.

3/5

B

GI discomfort²

Confidence: High

Stomach upset, diarrhea, vomiting, headache, dizziness, rash, and drowsiness are practical tolerance issues reported by safety summaries.

Note Useful for product comparison and stop-and-review cues.

2/5

B

Legal / regulatory risk²

Confidence: Medium

Regulatory treatment differs by market; Germany BfR issued a 2024 caution for food supplements and says no safe intake guidance value could be derived.

Note Do not present one country-specific risk assessment as a global ban.

3/5

B

Evidence uncertainty¹

Confidence: High

Benefit trials are generally short and product-variable, while long-term safety is not well established.

Note NCCIH notes short-term safety may be acceptable for some users but long-term conclusions are not available.

3/5

B

GI, drowsiness, headache, dizziness, rash²stomach upset, diarrhea, vomiting, drowsiness, headache, dizziness, rash

NCCIH and BfR list practical tolerance issues. LiverTox and case series add rare but clinically important liver-injury concern, so unexplained liver symptoms should be a stop-and-review signal rather than a reason to continue or escalate.

06

Legal and regulatory status

country-specific supplement rules²

In the United States, ashwagandha products are sold under dietary-supplement rules rather than preapproved drug rules. In Germany, BfR issued a 2024 food-supplement risk communication advising specific groups to avoid use and noting that no safe intake guidance value could be derived. Do not treat either position as a global legal rule.

07

FAQ

Is Ashwagandha a nootropic?

⁶

Only in a limited, indirect sense. The best practical evidence is closer to stress/rest support than a strong direct focus, memory, or productivity effect.

What dose is typical?

⁵

A common comparison range is 300-600 mg/day of extract, but plant part, extract ratio, and withanolide standardization can change what that number means.

How long are studies usually?

⁵

Many adult trials run for several weeks, often around 8 weeks. That is a study window, not a recommended cycle or proof of long-term safety.

Who should avoid or get expert review first?

¹

Pregnant or lactating users, children, people with liver disease history, thyroid or autoimmune disorders, upcoming surgery, hormone-sensitive prostate cancer context, sedating stacks, or relevant prescription drugs should get qualified review first rather than treat this as routine self-experimentation.

08

Ashwagandha

Names, aliases and forms

Potential effects and evidence map

Typical dosages and timing

Onset, duration and tolerance

Safety, side effects and risk profile

Legal and regulatory status

FAQ

Is Ashwagandha a nootropic?

What dose is typical?

How long are studies usually?

Who should avoid or get expert review first?

References